The endothelin a receptor antagonist LU 135252 protects the myocardium from neutrophil injury during ischaemia/reperfusion

Cardiovascular Research

Volumn 39, Issue 3, 1998, Pages 674-682

  Gonon, Adrian T ^a   Wang, Qing Dong ^a   Pernow, John ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Endothelin 1; ET(A) receptor; Ischaemia; LU 135252; Neutrophils; Rat; Reperfusion

Indexed keywords

2 (4,6 DIMETHOXYPYRIMIDIN 2 YLOXY) 3 METHOXY 3,3 DIPHENYL PROPIONIC ACID; DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; ISOLATED HEART; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANALYSIS OF VARIANCE; ANIMALS; CORONARY CIRCULATION; ENDOTHELIN-1; HUMANS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NEUTROPHILS; PHENYLPROPIONATES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; REPERFUSION;

EID: 0032169202     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00167-9     Document Type: Article

References (39)

1. Yanagisawa M., Kurihara H., Kimura S.et al. Endothelin: a novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 322:1988;411-415.
2. Rubanyi G.M., Polokoff M.A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 46:1994;325-415.
3. Lerman A., Edwards B.S., Hallet J.W.et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. New Engl J Med. 325:1991;997-1001.
4. Miyauchi T., Yanagisawa M., Tomizawa T.et al. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 2:1989;53-54.
5. Pernow J., Boutier J.F., Franco-Cereceda A.et al. Potent selective vasoconstrictor effects of endothelin in the pig kidney in vivo. Acta Physiol Scand. 134:1988;573-574.
6. Nichols A.J., Koster P.F., Ohlstein E.H. The effect of diltiazem on the coronary haemodynamic and cardiac functional effect produced by intracoronary administration of endothelin-1 in the anaesthetized dog. Br J Pharmacol. 99:1990;597-601.
7. Ezra D., Goldstein R.E., Czaja J.F., Feuerstein G.Z. Lethal ischemia due to intracoronary endothelin in pigs. Am J Physiol. 257:1989;H339-H343.
8. Arai H., Hori S., Aramori I.et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 348:1990;730-732.
9. Sakurai T., Yanagisawa M., Takuwa Y.et al. Cloning of a cDNA encoding a non isopeptide selective subtype of the endothelin receptor. Nature. 348:1990;732-735.
10. DeNucci G., Thomas R., D'Orleans-Juste P.et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA. 85:1988;9797-9800.
11. Tønnessen T., Giaid A., Saleh D.et al. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res. 76:1995;767-772.
12. Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Cardiovasc Res. 69:1991;370-377.
13. A receptor-mediated coronary vasoconstriction after coronary thrombosis and thrombolysis in pigs. J Cardiovasc Pharmacol. 26:1995;770-776.
14. Saito T., Furshimi E., Abe T. Augmented contractile response to endothelin and blunted endothelium-dependent relaxation in post-ischemic reperfused coronary arteries. Jpn Circ J. 56:1992;657-670.
15. Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res. 69:1991;370-377.
16. Grover G.J., Dzwonczyk S., Parham C.S. The endothelin-1 receptor antagonist BQ 123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res. 27:1993;1613-1618.
17. Wang Q.-D., Li X.-S., Lundberg J.M., Pernow J. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc Res. 29:1995;805-812.
18. Gómez Garre D., Guerra M., González E.et al. Aggregation of human polymorphonuclear leukocytes by endothelin: role of platelet activating factor. Eur J Pharmacol. 224:1992;167-172.
19. López Farré A., Riesco A., Moliz M.et al. Inhibition by L-arginine of the endothelin-mediated increase in cytosolic calcium in human neutrophils. Biochem Biophys Res Commun. 173:1991;496-500.
20. Elferink J.G.R., DeKoster B.M. Endothelin-induced activation of neutrophil migration. Biochem Pharmacol. 48:1994;865-871.
21. Ishida K., Takshige K., Minakami S. Endothelin-1 enhances superoxide generation of human neutrophils stimulated by the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine. Biochem Biophys Res Commun. 178:1990;884-891.
22. López Farré A., Riesco A., Espinosa G.et al. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation. 88:1993;1166-1171.
23. Hansen P.R. Role of neutrophils in myocardial ischemia and reperfusion. Circulation. 91:1995;1872-1885.
24. Wright D.G. Human neutrophil degranulation. Methods Enzymol. 162:1988;538-551.
25. Shandelya S.M.L., Kuppusamy P., Weisfeldt M.L., Zweier J.L. Evaluation of the role of polymorphonuclear leukocytes on contractile function in myocardial reperfusion injury. Evidence for plasma-mediated leukocyte activation. Circulation. 87:1993;536-546.
26. Münter K., Hergenröder L., Unger L., Kirchengast M. Oral treatment with a selective ETA-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm Pharmacol Lett. 6:1996;90-92.
27. Burke S.E., Nelson R.A. Endothelin-receptor antagonist FR 139317 reduces infarct size in a rabbit model when given before, but not after, coronary artery occlusion. J Cardiovasc Pharmacol. 29:1997;87-92.
28. Krause S.M., Lynch J.J. jr., Stabilito I.I., Woltmann R.F. Intravenous administration of the endothelin-1 antagonist BQ 123 does not ameliorate myocardial ischaemic injury following acute coronary occlusion in the dog. Cardiovasc Res. 28:1994;1672-1678.
29. McMurdo L., Thiemermann C., Vane J.R. The effects of the ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion. Br J Pharmacol. 112:1994;75-80.
30. Gonon AT, Wang Q-D, Shimizu M, Pernow J. The novel non-peptide selective endothelin A receptor antagonist LU 135252 protects against myocardial ischaemic and reperfusion injury in the pig. Acta Physiol Scand 1998, in press.
31. Wang Q.-D., Li X.-S., Pernow J. Characterization of endothelin-1-induced vascular effects in the rat heart by using endothelin receptor antagonists. Eur J Pharmacol. 271:1994;25-30.
32. Sessa W.C., Kaw S., Hecker M., Vane J.R. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun. 174:1991;613-618.
33. Sessa W.C., Kaw S., Zembowicz A.et al. Human polymorphonuclear leukocytes generate and degrade endothelin-1 by two distinct neutral proteases. J Cardiovasc Pharmacol. 17:1991;S34-S38.
34. Patrignani P., Del Maschio A., Bazzoni G.et al. Inactivation of endothelin by polymorphonuclear leukocyte-derived lytic enzymes. Blood. 78:1991;2715-2720.
35. Wright C.D., Cody W.L., Dunbar J.B. jret al. Characterization of endothelins as chemoattractants for human neutrophils. Life Sci. 55:1994;1633-1641.
36. Hayasaki Y., Nakajima M., Kitano Y.et al. ICAM-1 expression on cardiac myocytes and aortic endothelial cells via their specific endothelin receptor subtype. Biochem Biophys Res Commun. 229:1996;817-824.
37. Pabla R., Buda A.J., Flynn D.M.et al. Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ Res. 78:1996;65-72.
38. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 88:1991;4651-4655.
39. DeCaterina R., Libby P., Peng H.et al. Nitric oxide decreases cytokine-induced endothelial activation: NO selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 96:1995;60-68.